A Proof of Concept for the Use of Lung Ultrasound in the Diagnostic Approach of Pulmonary Hypertension, CHEST, March 2026

The authors of a study recently published on CHEST retrospectively analyzed data from adult patients enrolled in the French Pulmotension registry (Commission Nationale de l’Informatique et des Libertés No. 842063) from the Limoges Competence Center between May 1, 2020, and May 1, 2021. Inclusion criteria were the following: (1) confirmed pulmonary hypertension (PH) diagnosed by […]

A Proof of Concept for the Use of Lung Ultrasound in the Diagnostic Approach of Pulmonary Hypertension, CHEST, March 2026 Read Post »

Treatment paradigm shifts in pulmonary arterial hypertension: evidence from a phase 3 study in Asia on sotatercept, JACC, March 3, 2026

A Japanese study has confirmed that sotatercept works just as well in Asian patients, even though pulmonary arterial hypertension presents somewhat differently in the Asian population: patients tend to have longer disease duration, more severe baseline profiles, and are more frequently on intensive triple therapy including parenteral prostacyclin. This was a regional Phase 3, open-label

Treatment paradigm shifts in pulmonary arterial hypertension: evidence from a phase 3 study in Asia on sotatercept, JACC, March 3, 2026 Read Post »

Methamphetamine-Associated pulmonary arterial hypertension: a growing and distinct patient population, Journal of Heart and Lung Transplant, March 5, 2026

A large US claims-based study has shed light on a worrying trend: pulmonary arterial hypertension linked to methamphetamine use (Meth-APAH) is rising fast — up 93% between 2018 and 2022, a rate disproportionate to the general rise in methamphetamine use itself. Compared to other pulmonary arterial hypertension patients, those with Meth-APAH tend to be younger,

Methamphetamine-Associated pulmonary arterial hypertension: a growing and distinct patient population, Journal of Heart and Lung Transplant, March 5, 2026 Read Post »

2025 expert consensus on the use of parenteral prostanoids in incident and prevalent PAH patients: The Italian perspective, Vascular Pharmacology, February 28, 2026

A consensus document featuring 10 statements, the main focus of which was the use of parenteral prostanoids, was developed by eight experts in pulmonary arterial hypertension during in-person and web-based meetings. Forty-six Italian physicians were invited online to rate each statement, indicating their agreement, neutrality or disagreement. These consensus statements are intended to support physicians

2025 expert consensus on the use of parenteral prostanoids in incident and prevalent PAH patients: The Italian perspective, Vascular Pharmacology, February 28, 2026 Read Post »

Comparing survival and comorbidities between two sub-groups of pulmonary arterial hypertension from the Spanish REHAP Registry, Rheumatology (Oxford), February 27, 2026

A retrospective study based on data from the Spanish pulmonary arterial hypertension Registry (REHAP) set out to compare the demographic and clinical profiles, comorbidity burden, and survival rates of patients with connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) against those with idiopathic pulmonary arterial hypertension (IPAH). The study, covering the period 2014–2023, included 757 patients

Comparing survival and comorbidities between two sub-groups of pulmonary arterial hypertension from the Spanish REHAP Registry, Rheumatology (Oxford), February 27, 2026 Read Post »

Ensuring cultural relevance in pulmonary arterial hypertension QOL questionnaire adaptation: the Thai emPHasis-10 case, Journal of Patient-Reported Outcomes, February 20, 2026

The emPHasis-10 questionnaire is a specialized tool for assessing health-related quality of life in pulmonary arterial hypertension patients. A comprehensive validation process was undertaken by researchers in Thailand including forward-backward translation, expert content validity assessment using Item-Objective Congruence (IOC) index by five specialists, and reliability testing with 20 Thai PAH patients using both internal consistency

Ensuring cultural relevance in pulmonary arterial hypertension QOL questionnaire adaptation: the Thai emPHasis-10 case, Journal of Patient-Reported Outcomes, February 20, 2026 Read Post »

Heart and lung machine (ECMO) boosts survival for pregnant women with pulmonary arterial hypertension and pregnancy in a case series, Pulmonary Hypertension News, February 2, 2026

Pulmonary Hypertension News published a report on February 2, 2026, about a case series and literature review found that ECMO (extracorporeal membrane oxygenation)—a life-support machine that temporarily replaces heart and lung function—significantly improves survival in pregnant women with severe pulmonary arterial hypertension (PAH). The study documented five cases where the machine was used as rescue

Heart and lung machine (ECMO) boosts survival for pregnant women with pulmonary arterial hypertension and pregnancy in a case series, Pulmonary Hypertension News, February 2, 2026 Read Post »

Pulmonary arterial hypertension: right ventricular phenotyping to improve risk assessment at follow-up, European Heart Journal, February 6, 2026

An Italian study examined whether echocardiographic patterns of right heart changes could improve risk prediction in pulmonary arterial hypertension patients beyond current tools. Researchers defined four phenotypes based on right ventricular size and function, then followed patients for nearly 4 years. They found that these echo-based classifications provided additional prognostic information independent of existing risk

Pulmonary arterial hypertension: right ventricular phenotyping to improve risk assessment at follow-up, European Heart Journal, February 6, 2026 Read Post »

Early pulmonary arterial hypertension diagnosis improves five-year survival, Mayo Clinic study finds, Pulmonary Hypertension News, January 7, 2026

A recent study published in Pulmonary Circulation, summarised in an article by Andrea Lob on Pulmonary Hypertension News, found that early diagnosis of pulmonary arterial hypertension (PAH) – within six months of first healthcare contact for symptoms – improves five-year survival by 42 percentage points compared to delayed diagnosis (two years or more). Five-year survival

Early pulmonary arterial hypertension diagnosis improves five-year survival, Mayo Clinic study finds, Pulmonary Hypertension News, January 7, 2026 Read Post »

Self-management in pulmonary arterial hypertension: insights from patient interviews, Patient Preference and Adherence Journal, January 17, 2026

Twelve pulmonary arterial hypertension patients followed at the Fuwai Central China Cardiovascular Hospital in Zhengzhou City in the Henan Province, China, were interviewed to understand their self-management challenges. The findings were published in the Patient Preference and Adherence Journal on January 17, 2026, and reveal significant barriers to effective disease self-management across two main categories.

Self-management in pulmonary arterial hypertension: insights from patient interviews, Patient Preference and Adherence Journal, January 17, 2026 Read Post »

Pulmonary arterial hypertension associated with exposure to toxic rapeseed oil, European Respiratory Journal Open Research, December 19, 2025

A prospective analysis from the Spanish Registry of pulmonary arterial hypertension (REHAP) examined 59 patients diagnosed with toxic oil syndrome-associated pulmonary arterial hypertension (TOS-PAH) between 1997 and 2025, providing new clinical, pathological and genetic insights into this historically significant form of drug-induced pulmonary arterial hypertension. Key findings: The patient cohort was 63% female with a

Pulmonary arterial hypertension associated with exposure to toxic rapeseed oil, European Respiratory Journal Open Research, December 19, 2025 Read Post »

The acute pulmonary vasoreactivity in pulmonary arterial hypertension revisited in the contemporary era, International Journal of Cardiology Heart and Vasculature, February 2026

During right heart catheterization (RHC), the “acute vasodilator test” offers valuable insights into pulmonary circulation by evaluating vasoreactivity. A positive result identifies a rare pulmonary arterial subtype that may benefit from long-term calcium-channel blocker therapy (the so called “responders”). A recent study re-examines the applications, criteria, and objectives of acute vasodilator testing in pulmonary hypertension

The acute pulmonary vasoreactivity in pulmonary arterial hypertension revisited in the contemporary era, International Journal of Cardiology Heart and Vasculature, February 2026 Read Post »

Durability of sotatercept response in pulmonary arterial hypertension: Insights from extended real-world follow-up, International Journal of Cardiology, January 2, 2026

A retrospective cohort study using data from 103 healthcare organizations compared 454 pulmonary arterial hypertension patients receiving sotatercept to 963.386 pulmonary arterial hypertension patients not receiving sotatercept. After propensity score matching to balance baseline characteristics, 346 patients per group were analyzed over an average follow-up of approximately 6-8 months. The sotatercept group demonstrated dramatically lower

Durability of sotatercept response in pulmonary arterial hypertension: Insights from extended real-world follow-up, International Journal of Cardiology, January 2, 2026 Read Post »

Inserm, France’s National Institute of Health and Medical Research, awards its 2025 Grand Prix to Prof. Marc Humbert for his role in transforming pulmonary hypertension care

Professor Marc Humbert, one of the world’s leading specialists in pulmonary arterial hypertension (PAH), has been awarded the prestigious Inserm Grand Prize in recognition of his extraordinary career dedicated to understanding and treating this life-threatening disease. Inserm is the French National Institute of Health and Medical Research. From Orphan Disease to Hope When Prof. Humbert

Inserm, France’s National Institute of Health and Medical Research, awards its 2025 Grand Prix to Prof. Marc Humbert for his role in transforming pulmonary hypertension care Read Post »

Male survival disadvantage in pulmonary hypertension: independent of aetiology, age, disease severity, comorbidities and treatment, EBioMedicine, December 16, 2025

The Pulmonary Vascular Research Institute (PVRI) GoDeep meta-registry integrates data from international pulmonary hypertension registries, from which 21,123 incident hemodynamically fully characterised patients were analysed to investigate the influence of sex on survival of patients. Findings revealed that male patients have significantly higher mortality rates than female patients across all types of pulmonary hypertension. This survival

Male survival disadvantage in pulmonary hypertension: independent of aetiology, age, disease severity, comorbidities and treatment, EBioMedicine, December 16, 2025 Read Post »

The Discovery of Inhaled Prostanoids for Pulmonary Hypertension, Prof. Werner Seeger, Pulmonary Circulation, December 18, 2025

A very interesting article by Prof. Werner Seeger recounts the discovery and development of inhaled prostanoids for pulmonary hypertension at the Giessen Pulmonary Hypertension center (Germany) in the late 1980s-1990s (§). Initially researching acute lung injury/Acute Respiratory Distress Syndrome (ARDS), researchers at Giessen observed that while intravenous vasodilators worsened ventilation/perfusion mismatch, aerosolized prostacyclin (PGI2) reduced

The Discovery of Inhaled Prostanoids for Pulmonary Hypertension, Prof. Werner Seeger, Pulmonary Circulation, December 18, 2025 Read Post »

Use of Sotatercept to Facilitate Transition From Intravenous to Oral Prostacyclin Therapy for Pulmonary Arterial Hypertension, Clinical Respiratory Journal, December 19, 2025

Parenteral prostacyclin therapy remains the cornerstone for high-risk pulmonary arterial hypertension (PAH) patients but is limited by complications and reduced quality of life. A case series of eight high-risk patients demonstrated that adding sotatercept successfully enabled transition from intravenous to oral prostacyclin therapy. All patients received background dual therapy with endothelin receptor antagonists and phosphodiesterase-5

Use of Sotatercept to Facilitate Transition From Intravenous to Oral Prostacyclin Therapy for Pulmonary Arterial Hypertension, Clinical Respiratory Journal, December 19, 2025 Read Post »

ASPYRE-1 study: An Italian multicenter prospective study on pulmonary hypertension modality of death and validation of reveal risk score, Vascular Pharmacology, November 29, 2025

The ASPYRE-1 study presents the baseline characteristics of patients enrolled in the national prospective registry created through the Italian Network on Pulmonary Arterial Hypertension (IPHNET). The registry was established in 2014 with the aim of better understanding the contemporary profile of Italian pulmonary arterial hypertension patients and to support future analyses on risk stratification and

ASPYRE-1 study: An Italian multicenter prospective study on pulmonary hypertension modality of death and validation of reveal risk score, Vascular Pharmacology, November 29, 2025 Read Post »

Patient-reported Functional Class (FC) may better reflect pulmonary hypertension burden than physician-assigned Functional Class, CHEST, November 27, 2025

A new study published recently on CHEST evaluated whether the Pulmonary Hypertension Functional Class Self-Report (PH-FC-SR)—a patient-reported version of the World Health Organisation (WHO) Functional Class—captures functional status in a way that reflects patients’ real experiences. Study Overview Eighty-nine adults with pulmonary hypertension (Groups 1–5) from the Cleveland Clinic and Mayo Clinic completed an online

Patient-reported Functional Class (FC) may better reflect pulmonary hypertension burden than physician-assigned Functional Class, CHEST, November 27, 2025 Read Post »

GDF15 is a promising biomarker for distinguishing pulmonary veno-occlusive disease (PVOD) and pulmonary arterial hypertension (PAH), Journal of Clinical Investigation, November 20, 2025

Pulmonary veno-occlusive disease (PVOD) is a rare, severe World Health Organisation Group 1 pulmonary arterial hypertension (PAH) subtype with poor survival. pulmonary arterial hypertension-targeted vasodilators can cause life-threatening pulmonary edema in Pulmonary veno-occlusive disease, underscoring the need for diagnostic tools to distinguish it from other pulmonary arterial hypertension subtypes The findings of a study recently

GDF15 is a promising biomarker for distinguishing pulmonary veno-occlusive disease (PVOD) and pulmonary arterial hypertension (PAH), Journal of Clinical Investigation, November 20, 2025 Read Post »

TRANSLATE »
Scroll to Top